Patents by Inventor Daniel Galtieri

Daniel Galtieri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT FOR DOPAMINERGIC DISORDERS
    Publication number: 20230241047
    Abstract: The present invention provides systems, compositions and methods for treatment of dopaminergic disorders (e.g., Parkinson's disease) using the combination of a first compound that inhibits a voltage-gated calcium channel of the type Cav1.3 (e.g., a dihydropyridine such as isradipine), and a second compound that is monoamine oxidase inhibitor and/or is a nitric oxide synthase inhibitor (e.g., rasagiline or derivative thereof).
    Type: Application
    Filed: April 10, 2023
    Publication date: August 3, 2023
    Inventors: Dalton J. Surmeier, Javier Sanchez, Jaime Guzman, Enrico Zampese, Daniel Galtieri, Ema Ilijic
  • TREATMENT FOR DOPAMINERGIC DISORDERS
    Publication number: 20220304994
    Abstract: The present invention provides systems, compositions and methods for treatment of dopaminergic disorders (e.g., Parkinson's disease) using the combination of a first compound that inhibits a voltage-gated calcium channel of the type Cav1.3 (e.g., a dihydropyridine such as isradipine), and a second compound that is monoamine oxidase inhibitor and/or is a nitric oxide synthase inhibitor (e.g., rasagiline or derivative thereof).
    Type: Application
    Filed: June 14, 2022
    Publication date: September 29, 2022
    Inventors: Dalton J. Surmeier, Javier Sanchez, Jaime Guzman, Enrico Zampese, Daniel Galtieri, Ema Ilijic
  • TREATMENT FOR DOPAMINERGIC DISORDERS
    Publication number: 20200323835
    Abstract: The present invention provides systems, compositions and methods for treatment of dopaminergic disorders (e.g., Parkinson's disease) using the combination of a first compound that inhibits a voltage-gated calcium channel of the type Cav1.3 (e.g., a dihydropyridine such as isradipine), and a second compound that is monoamine oxidase inhibitor and/or is a nitric oxide synthase inhibitor (e.g., rasagiline or derivative thereof).
    Type: Application
    Filed: February 12, 2020
    Publication date: October 15, 2020
    Inventors: Dalton J. Surmeier, Javier Sanchez, Jaime Guzman, Enrico Zampese, Daniel Galtieri, Ema Ilijic
  • TREATMENT FOR DOPAMINERGIC DISORDERS
    Publication number: 20170182018
    Abstract: The present invention provides systems, compositions and methods for treatment of dopaminergic disorders (e.g., Parkinson's disease) using the combination of a first compound that inhibits a voltage-gated calcium channel of the type Cav1.3 (e.g., a dihydropyridine such as isradipine), and a second compound that is monoamine oxidase inhibitor and/or is a nitric oxide synthase inhibitor (e.g., rasagiline or derivative thereof).
    Type: Application
    Filed: October 11, 2016
    Publication date: June 29, 2017
    Inventors: Dalton J. Surmeier, Javier Sanchez, Jaime Guzman, Enrico Zampese, Daniel Galtieri, Ema Ilijic
  • Treatment for dopaminergic disorders
    Patent number: 9463186
    Abstract: The present invention provides systems, compositions and methods for treatment of dopaminergic disorders (e.g., Parkinson's disease) using the combination of a first compound that inhibits a voltage-gated calcium channel of the type Cav1.3 (e.g., a dihydropyridine such as isradipine), and a second compound that is monoamine oxidase inhibitor and/or is a nitric oxide synthase inhibitor (e.g., rasagiline or derivative thereof).
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: October 11, 2016
    Assignee: Northwestern University
    Inventors: Dalton J. Surmeier, Javier Sanchez, Jaime Guzman, Enrico Zampese, Daniel Galtieri, Ema Ilijic
  • TREATMENT FOR DOPAMINERGIC DISORDERS
    Publication number: 20140309260
    Abstract: The present invention provides systems, compositions and methods for treatment of dopaminergic disorders (e.g., Parkinson's disease) using the combination of a first compound that inhibits a voltage-gated calcium channel of the type Cav1.3 (e.g., a dihydropyridine such as isradipine), and a second compound that is monoamine oxidase inhibitor and/or is a nitric oxide synthase inhibitor (e.g., rasagiline or derivative thereof).
    Type: Application
    Filed: April 15, 2014
    Publication date: October 16, 2014
    Applicant: Northwestern University
    Inventors: Dalton J. Surmeier, Javier Sanchez, Jaime Guzman, Enrico Zampese, Daniel Galtieri, Ema Ilijic